Country spotlights
What happens when access opens up.
Three countries that ran the experiment, and a running snapshot of the reimbursement wins, gaps and campaigns happening right now.
Denmark — 2SENSE
14 days of data changed behaviour.
455 people with type 2 diabetes not on insulin — a group almost universally excluded from reimbursement — wore a sensor for two weeks. 340 completed follow-up.
found the sensor educational.
changed their behaviour.
learned how food affects their glucose.
reached estimated HbA1c ≤48 mmol/mol.
Update — October 2026
Big win: the government has proposed DKK 200 million a year (2027–2030) for sensor-based glucose monitors in its 2027 finance bill — after years of advocacy by Diabetesforeningen.
Today only around 1% of Danes with type 2 diabetes use a sensor. The proposal still needs a parliamentary majority to become law.
"Every type 2 patient should be equipped with a sensor for a period at the onset of illness."
Sources: Diabetesforeningen, "2Sense: Viden bliver til handling" (2024); Diabetesforeningen, "Stor sejr: Regeringen foreslår millioner til sensorer" (October 2026).
Sweden — type 2 diabetes
HbA1c falls — and stays down.
3,202 adults with type 2 diabetes in the Swedish National Diabetes Register, tracked after starting flash glucose monitoring. The biggest gains went to those who needed them most.
mean HbA1c at 6 months (n=711).
sustained at 12 months (n=538).
for insulin-treated users starting above 12% HbA1c.
Source: Eeg-Olofsson K, et al., Diab Vasc Dis Res 2023;20(1).
Malta — advocacy works
From "not available" to 950 people covered.
- 2021
A six-month pilot gives CGMs to under-16s with T1D, showing clear gains in control and quality of life.
- 2022–24
Access is extended to older age groups on the strength of the pilot.
- Today
≈950 of Malta's ~1,600 people with T1D have reimbursed access — the fight for the remaining 40% continues.
Source: IDF Europe Compendium (2025) — Maltese Diabetes Association case study.
Country by country
Wins, gaps and fights in motion.
Recent reimbursement moves, sourced to national associations, official gazettes and press. Click any card for the source.
DKK 200M a year proposed for sensors
After sensors for type 2 diabetes entered the government's coalition agreement, the 2027 finance bill proposal now earmarks DKK 200M/year from 2027 to 2030, shared with women's health and fertility. Only ~1% of Denmark's 348,500 people with T2D have a sensor today.
Hybrid closed-loop reimbursed
Omnipod 5 paired with Dexcom G7 added to national reimbursement — the first tubeless hybrid closed-loop system funded in France.
FAND demands equal T2 access
44th National Assembly calls for uniform CGM access for all T2 patients with clinical indication. Sardinia still applies criteria frozen at 2016.
5,878 adults still get nothing
State funds sensors only for pregnant women and diabetes-related amputees; coverage ends at age 18 (sensors) / 24 (pumps). T1s protested outside the Saeima.
Adults finally get one sensor a month
New regulation ends the rule that stripped adults over 18 of sensor coverage. T1s on ≥4 daily insulin doses now receive one sensor per month.
500–700 T1s denied on a technicality
National scheme exists after 2023 HIQA recommendation, but complex or delayed T1 diagnoses are excluded. Diabetes Ireland is asking €1M in Budget 2026.
Next
Back to the overview